La chaîne d'options affiche les données clés des options sur actions de DBV Technologies à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour DBV Technologies..

DBV Technologies (NASDAQ:DBVT) Stock, Chaîne d'Options

DBV TECHNOLOGIES SA-SPON ADR

DBV Technologies

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

DBV Technologies S.A. - American Depositary Shares

DBV Technologies SA

DBV TECHNOLOGIES SA by DBV Technologies SA

Biotech

News

General

DBVT

DBV Technologies To Present New Clinical Data On VIASKIN Peanut And Cow's Milk Allergy Patches At EAACI 2025 Congress

Goldman Sachs analyst Rajan Sharma reinstates DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Sell and announces $7.25 price target.

Price Target

Initiation

Analyst Ratings

Goldman Sachs Reinstates Sell on DBV Technologies, Announces $7.25 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Ascendiant Capital raised Pro-Dex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) price target from $54 to $56. Ascendiant Capital analyst Edward Woo maintained a Buy rating. Pro-Dex shares closed at $46.24 on Friday. <a href="https://www.benzinga.com/quote/PDEX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. slashed the price target for Unity Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) from $4 to $2. HC Wainwright &amp; Co. analyst Matthew Caufield downgraded the stock from Buy to Neutral. Unity Biotechnology shares closed at $0.7790 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/UBX/analyst-ratings">view this stock</a>.</li>
<li>JMP Securities cut Churchill Downs Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) price target from $144 to $138. JMP Securities analyst Jordan Bender maintained a Market Outperform rating. Churchill Downs shares closed at $93.24 on Friday. See how other <a href="https://www.benzinga.com/quote/CHDN/analyst-ratings">analysts view this stock</a>.</li>
<li>JMP Securities increased the price target for DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) from $15 to $21. JMP Securities analyst Jonathan Wolleben maintained a Market Outperform rating. DBV Technologies shares closed at $8.41 on Friday. <a href="https://www.benzinga.com/quote/DBVT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group increased the price target for Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) from $85 to $100. Telsey Advisory Group analyst Joseph Feldman maintained a Market Perform rating. Dollar General shares closed at $101.39 on Friday. See how other <a href="https://www.benzinga.com/quote/DG/analyst-ratings">analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) price target from $30 to $14. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. Prothena shares settled at $6.58 on Friday. <a href="https://www.benzinga.com/quote/PRTA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group increased Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) price target from $82 to $95. Telsey Advisory Group analyst Joseph Feldman maintained a Market Perform rating. Dollar Tree shares closed at $88.17 on Friday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim cut Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) price target from $155 to $115. Guggenheim analyst Robert Drbul maintained a Buy rating. Target shares closed at $94.29 on Friday.  <a href="https://www.benzinga.com/quote/TGT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Chardan Capital cut the price target for Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) from $40 to $18. Chardan Capital analyst Rudy Li maintained a Buy rating. Prothena shares settled at $6.58 on Friday. <a href="https://www.benzinga.com/quote/PRTA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo raised PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) price target from $68 to $74. Wells Fargo analyst Tiago Fauth maintained an Overweight rating. PTC Therapeutics shares closed at $45.93 on Friday. <a href="https://www.benzinga.com/quote/PTCT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying PTCT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-1024x582.png" alt="" class="wp-image-928475" style="width:643px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-1024x582.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-768x436.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/news/earnings/25/05/45585696/how-to-earn-500-a-month-from-dicks-sporting-goods-stock-ahead-of-q1-earnings"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45585696/how-to-earn-500-a-month-from-dicks-sporting-goods-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Dick&#8217;s Sporting Goods Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Markets

Trading Ideas

CHDN

DLTR

PDEX

PRTA

PTCT

PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday

WIIM

DBV Technologies shares are trading higher after JMP Securities raised its price target on the stock from $15 to $21 and maintained an Outperform rating.

<h3>Gainers</h3>
<ul>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) stock increased by 88.9% to $0.76 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) stock rose 34.55% to $0.88. The market value of their outstanding shares is at $35.4 million. </li>
<li>Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) stock moved upwards by 15.2% to $11.32. The market value of their outstanding shares is at $236.6 million. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) stock rose 11.47% to $1.35. The company's market cap stands at $88.8 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares moved upwards by 11.41% to $9.37. The market value of their outstanding shares is at $256.2 million. </li>
<li>Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) shares moved upwards by 11.25% to $4.44. The company's market cap stands at $292.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) stock decreased by 62.5% to $2.35 during Tuesday's pre-market session. The company's market cap stands at $253.1 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares decreased by 31.03% to $0.8. The market value of their outstanding shares is at $14.0 million. </li>
<li>Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) stock decreased by 26.9% to $4.81. The market value of their outstanding shares is at $258.9 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares fell 20.15% to $447.17. The company's market cap stands at $5.8 billion. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares decreased by 13.07% to $4.59. The company's market cap stands at $125.2 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock declined by 10.97% to $0.21. The company's market cap stands at $2.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BRNS

BSGM

IMNN

IOBT

NVCT

RCKT

STIM

VTAK

WORX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

JMP Securities analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Market Outperform and raises the price target from $15 to $21.

JMP Securities Maintains Market Outperform on DBV Technologies, Raises Price Target to $21

<h3>Gainers</h3>
<ul>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock moved upwards by 2412.3% to $5.12 during Tuesday's regular session. The company's market cap stands at $466.1 million. The company's, Q2 earnings came out 3 days ago. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock increased by 42.47% to $1.61. The company's market cap stands at $4.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock moved upwards by 23.28% to $0.28. The company's market cap stands at $5.0 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares increased by 22.5% to $431.22. The market value of their outstanding shares is at $5.6 billion. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) stock rose 18.79% to $1.68. The market value of their outstanding shares is at $307.3 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) shares increased by 17.2% to $1.35. The company's market cap stands at $53.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock fell 31.1% to $7.65 during Tuesday's regular session. The market value of their outstanding shares is at $4.5 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares decreased by 17.74% to $8.88. The company's market cap stands at $243.0 million. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) shares fell 15.14% to $0.28. The company's market cap stands at $8.1 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares decreased by 13.64% to $0.01. </li>
<li>Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) shares declined by 12.62% to $7.38. The company's market cap stands at $629.6 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares declined by 11.85% to $5.25. The company's market cap stands at $285.3 million. The company's, Q1 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALMS

AVXL

BIAF

EKSO

EYEN

PLRZ

PTIX

TELA

12 Health Care Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Septerna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) stock rose 74.9% to $11.77 during Wednesday's pre-market session. The market value of their outstanding shares is at $523.9 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares rose 63.63% to $3.24. The market value of their outstanding shares is at $9.8 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock moved upwards by 51.72% to $9.65. The market value of their outstanding shares is at $198.6 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares increased by 14.34% to $144.0. The market value of their outstanding shares is at $782.9 million. The company's, Q1 earnings came out yesterday. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock moved upwards by 14.01% to $12.53. The company's market cap stands at $342.7 million. </li>
<li>Advanced Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVB#NASDAQ">ADVB</a>) shares increased by 12.74% to $1.15. The company's market cap stands at $24.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock fell 46.3% to $0.02 during Wednesday's pre-market session. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares decreased by 29.44% to $0.06. The company's market cap stands at $1.5 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock decreased by 16.79% to $0.17. The market value of their outstanding shares is at $8.9 million. </li>
<li>EUDA Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EUDA#NASDAQ">EUDA</a>) shares decreased by 15.48% to $3.55. The company's market cap stands at $131.8 million. </li>
<li>GRAIL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) stock fell 13.15% to $37.25. The market value of their outstanding shares is at $1.3 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) shares fell 12.03% to $1.39. The market value of their outstanding shares is at $52.5 million. As per the press release, Q1 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADVB

APYX

AXDX

Euda Health Holdings Limited - Ordinary Shares

EUDA

GRAL

LUCY

NUTX

QNRX

SEPN

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Shares of Everus Construction Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECG#NYSE">ECG</a>) rose sharply in today's pre-market trading after the company<a href="https://www.benzinga.com/quote/ECG"> posted better-than-expected first-quarter results.</a>
Everus Construction Group reported quarterly earnings of 72 cents per share which beat the analyst consensus estimate of 43 cents per share. The company reported quarterly sales of $826.63 million which beat the analyst consensus estimate of $676.35 million.
Everus Construction shares jumped 14.7% to $59.00 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>HWH International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) rose 84.2% to $2.21 in pre-market trading after gaining 4% on Tuesday.</li>
<li>Innovative Eyewear, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) surged 54.1% to $3.05 in pre-market trading as the company posted a narrower-than-expected quarterly loss.</li>
<li>La Rosa Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRHC#NASDAQ">LRHC</a>) gained 40.2% to $0.1963 in pre-market trading.</li>
<li>Allurion Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NASDAQ">ALUR</a>) jumped 31% to $3.09 in pre-market trading.</li>
<li>DevvStream Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEVS#NASDAQ">DEVS</a>) gained 30.2% to $0.7422 in pre-market trading after the company signed a MoU with Fayafi Investment Holding to explore creation of &#8220;Fayafi x DevvStream Green Ventures.&#8221;</li>
<li>WEBUY GLOBAL LTD. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBUY#NASDAQ">WBUY</a>) surged 21.9% to $8.84 in pre-market trading after dipping more than 18% on Tuesday.</li>
<li>FingerMotion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNGR#NASDAQ">FNGR</a>) climbed 16.4% to $5.10 in pre-market trading after gaining 24% on Tuesday.</li>
<li>DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) gained 16.3% to $12.78 in pre-market after gaining 8% on Tuesday.</li>
<li>Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) gained 13.9% to $3.37 in pre-market trading after the company reported better-than-expected quarterly financial results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares fell 44.2% to $0.0159 in pre-market trading after dipping 92% on Tuesday.</li>
<li>TEN Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHLD#NASDAQ">XHLD</a>) fell 35.3% to $0.89 in pre-market trading after jumping 112% on Tuesday.</li>
<li>Accelerate Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) fell 33% to $0.0590 in today's pre-market trading after tumbling 34% on Tuesday.</li>
<li>X3 Holdings Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) shares dipped 24.2% to $1.60 in pre-market trading after gaining 88% on Tuesday.</li>
<li>Actelis Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) fell 21.3% to $0.63 in pre-market trading after posting weak quarterly sales.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) shares fell 16.7% to $6.11 in pre-market trading after Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) announced plans to sell some of its Aurora Innovation stake in a senior notes offering.</li>
<li>Abpro Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) dipped 16.2% to $0.1719 in pre-market trading.</li>
<li>GRAIL, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) shares tumbled 14.1% to $36.86 in pre-market trading after reporting weak quarterly sales.</li>
<li>American Eagle Outfitters, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) declined 13.8% to $10.96 in pre-market trading after the company guided first-quarter revenue down and withdrew FY25 guidance.</li>
<li>Allot Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLT#NASDAQ">ALLT</a>) fell 8.1% to $7.79 in pre-market trading after gaining 8% on Tuesday.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

ABSI

ALLT

ALUR

ASNS

DEVS

FNGR

LRHC

UBER

WBUY

XHLD

XTKG

Why Everus Construction Group Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

HC Wainwright &amp; Co. analyst Andrew Fein maintains DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Buy and raises the price target from $7 to $16.

HC Wainwright & Co. Maintains Buy on DBV Technologies, Raises Price Target to $16

JMP Securities analyst Steven Delaney maintains DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Market Outperform and raises the price target from $10 to $15.

JMP Securities Maintains Market Outperform on DBV Technologies, Raises Price Target to $15

DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) reported quarterly losses of $(0.26) per share. This is a 7.14 percent increase over losses of $(0.28) per share from the same period last year.

Earnings

DBV Technologies Q1 EPS $(0.26) Up From $(0.28) YoY

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock moved upwards by 40.8% to $1.32 during Monday's after-market session. The market value of their outstanding shares is at $231.0 million. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock increased by 8.77% to $0.77. The market value of their outstanding shares is at $61.6 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock rose 8.29% to $2.48. The market value of their outstanding shares is at $6.1 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock rose 7.9% to $0.09. The company's market cap stands at $1.3 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares moved upwards by 6.55% to $0.3. The market value of their outstanding shares is at $4.2 million. </li>
<li>Genfit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) stock increased by 6.16% to $3.79. The market value of their outstanding shares is at $188.9 million. The company's, FY earnings came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) shares declined by 12.6% to $8.37 during Monday's after-market session. The company's market cap stands at $712.2 million. </li>
<li>Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) shares decreased by 10.38% to $3.8. The market value of their outstanding shares is at $170.1 million. </li>
<li>Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) shares fell 8.97% to $1.93. The market value of their outstanding shares is at $60.2 million. </li>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) shares decreased by 8.53% to $0.33. The company's market cap stands at $10.7 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares fell 7.31% to $8.5. The market value of their outstanding shares is at $232.3 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock declined by 6.95% to $2.41. The company's market cap stands at $6.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

CTMX

CYCC

FORA

GNFT

LIPO

ONCO

RLMD

TVGN

YMAB

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares moved upwards by 105.9% to $9.7 during Friday's regular session. The company's market cap stands at $15.9 million. </li>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) shares rose 78.39% to $0.62. The company's market cap stands at $224.1 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 40.92% to $5.51. The market value of their outstanding shares is at $113.0 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock rose 29.3% to $0.56. The market value of their outstanding shares is at $14.0 million. As per the press release, Q4 earnings came out today. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) shares moved upwards by 14.24% to $0.88. The market value of their outstanding shares is at $23.5 million. </li>
<li>Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) shares increased by 14.09% to $0.78. The company's market cap stands at $42.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares decreased by 72.5% to $0.04 during Friday's regular session. </li>
<li>Milestone Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) shares declined by 60.37% to $0.89. The market value of their outstanding shares is at $47.5 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares fell 51.28% to $0.02. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares decreased by 29.73% to $1.6. The company's market cap stands at $18.4 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares declined by 27.68% to $2.64. The company's market cap stands at $1.7 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock fell 26.02% to $25.8. The market value of their outstanding shares is at $335.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LGMK

LXRX

MIST

PRLD

PRTG

SNSE

STSS

VERO

12 Health Care Stocks Moving In Friday's Intraday Session

DBV Technologies SA &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>), a clinical-stage biopharmaceutical company focused on pediatric allergies, <a href="https://www.benzinga.com/pressreleases/25/03/g44528665/dbv-technologies-announces-financing-of-up-to-306-9-million-284-5-million-to-advance-viaskin-peanu">announced a financing deal</a> of up to $306.9 million (€284.5 million). The stock is up some 50% to $5.90 during Friday&#8217;s session following the deal.
What To Know: The company will receive $125.5 million (€116.3 million) upon closing, with an additional $181.4 million (€168.2 million) possible if all warrants are exercised.
The funding will support working capital, the Viaskin Peanut program, a potential Biologics License Application, and a U.S. launch if approved. The financing, led by major healthcare investors, could dilute existing shareholders by up to 73.7%. 
CEO Daniel Tassé highlighted the company's alignment with the FDA on safety data, potentially expediting the BLA submission. The Phase 3 VITESSE study, exceeding enrollment expectations, aims for results in fourth-quarter 2025.
Read Also: <a href="https://www.benzinga.com/news/25/03/44539023/whats-going-on-with-ford-stock-2">What&#8217;s Going On With Ford Stock?</a>
<h2 class="wp-block-heading">How To Buy DBVT Stock</h2>
By now you're likely curious about how to participate in the market for DBV Technologies &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, DBVT has a 52-week high of $8.32 and a 52-week low of $2.20.

Why DBV Technologies (DBVT) Stock Is Skyrocketing

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 500 points on Friday.
The Dow traded down 1.21% to 41,788.66 while the NASDAQ fell 2.11% to 17,424.77. The S&amp;P 500 also fell, dropping, 1.49% to 5,608.74.
Check This Out: <a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock">Jim Cramer: Stryker Is A &#8216;Good&#8217; Company, Says He Likes This Utilities Stock</a>
Leading and Lagging Sectors Utilities shares jumped by 1.2% on Friday.
In trading on Friday, consumer discretionary shares fell by 2.8%.
Top Headline
The Federal Reserve&#8217;s preferred inflation gauge rose more than anticipated in February, underscoring the bumpy road back to the 2% target and throwing cold water on expectations for imminent interest rate cuts.
According to data released Friday by the Bureau of Economic Analysis, the Personal Consumption Expenditures (PCE) price index increased by 2.5% year-over-year, matching both the previous reading and economist forecasts of 2.5%. On a monthly basis, headline PCE rose 0.3%, in line with estimates.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares shot up 126% to $10.67 after the company reported new data for PORT-7 at the 2025 European Lung Cancer Congress.</li>
<li>Shares of Abacus Global Management, Inc. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NYSE">ABL</a>)got a boost, surging 13% to $8.11 following strong quarterly sales.</li>
<li>DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares were also up, gaining 48% to $6.00 after the company announced up to $307 million in financing to advance the Viaskin Peanut program.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Milestone Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) shares dropped 62% to $0.8550 after the company received a letter from the FDA for its new drug application for CARDAMYST nasal spray.</li>
<li>Shares of XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) were down 48% to $1.29 after the company priced its public offering at $1.36 per share.</li>
<li>AAR Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) was down, falling 16% to $57.37 after the company reported a third-quarter sales miss.</li>
</ul>
Commodities In commodity news, oil traded down 0.2% to $69.76 while gold traded up 0.7% at $3,112.20.
Silver traded up 0.7% to $35.340 on Friday, while copper rose 0.7% to $5.1545.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 declined 0.3%, Germany's DAX 40 fell 0.5% and France's CAC 40 declined 0.6%. Spain's IBEX 35 Index fell 0.5%, while London's FTSE 100 rose 0.1%.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 falling 1.80%, China's Shanghai Composite Index declining 0.67%, Hong Kong's Hang Seng Index dipping 0.65% and India's BSE Sensex falling 0.25%.
Economics
<ul>
<li>The Personal Consumption Expenditures (PCE) price index increased by 2.5% year-over-year, matching both the previous reading and economist forecasts of 2.5%. On a monthly basis, headline PCE rose 0.3%, in line with estimates.</li>
<li>Personal spending rose 0.4% month-over-month in February after a 0.3% contraction in January, but missing expectations for a 0.5% increase.</li>
<li>Personal income growth accelerated to 0.8%, above January&#8217;s 0.7% and well beyond the 0.4% estimate. </li>
<li>The University of Michigan consumer sentiment fell to 57 in March versus a preliminary reading of 57.9.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44534992/how-to-earn-500-a-month-from-pvh-stock-ahead-of-q4-earnings">How To Earn $500 A Month From PVH Stock Ahead Of Q4 Earnings</a></li>
</ul>
Photo: Shutterstock

Equities

Eurozone

Commodities

Intraday Update

XTIA

Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher

U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 100 points on Friday.
Following the market opening Friday, the Dow traded down 0.24% to 42,198.64 while the NASDAQ fell 0.57% to 17,701.94. The S&amp;P 500 also fell, dropping, 0.36% to 5,672.68.
Check This Out: <a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock">Jim Cramer: Stryker Is A &#8216;Good&#8217; Company, Says He Likes This Utilities Stock</a>
Leading and Lagging Sectors Utilities shares jumped by 0.6% on Friday.
In trading on Friday, consumer discretionary shares fell by 1.4%.
Top Headline
The Federal Reserve&#8217;s preferred inflation gauge rose more than anticipated in February, underscoring the bumpy road back to the 2% target and throwing cold water on expectations for imminent interest rate cuts.
According to data released Friday by the Bureau of Economic Analysis, the Personal Consumption Expenditures (PCE) price index increased by 2.5% year-over-year, matching both the previous reading and economist forecasts of 2.5%. On a monthly basis, headline PCE rose 0.3%, in line with estimates.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares shot up 170% to $12.79 after the company reported new data for PORT-7 at the 2025 European Lung Cancer Congress.</li>
<li>Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>)got a boost, surging 83% to $0.6359 after the company announced an exclusive license agreement with Novo Nordisk for LX9851.</li>
<li>DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares were also up, gaining 43% to $5.79 after the company announced up to $307 million in financing to advance the Viaskin Peanut program.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Milestone Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) shares dropped 64% to $0.7997 after the company received a letter from the FDA for its new drug applicationfFor CARDAMYST nasal spray.</li>
<li>Shares of XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) were down 48% to $1.2689 after the company priced its public offering at $1.36 per share.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) was down, falling 41% to $3.18. On Thursday, Wolfspeed announced the appointment of Robert Feurle as CEO, effective May 1, 2025.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $69.82 while gold traded up 0.5% at $3,106.80.
Silver traded up 0.5% to $35.255 on Friday, while copper rose 0.5% to $5.1440.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 declined 0.3%, Germany's DAX 40 fell 0.5% and France's CAC 40 dipped 0.6%. Spain's IBEX 35 Index fell 0.5%, while London's FTSE 100 rose 0.1%.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 falling 1.80%, China's Shanghai Composite Index declining 0.67%, Hong Kong's Hang Seng Index dipping 0.65% and India's BSE Sensex falling 0.25%.
Economics
<ul>
<li>The Personal Consumption Expenditures (PCE) price index increased by 2.5% year-over-year, matching both the previous reading and economist forecasts of 2.5%. On a monthly basis, headline PCE rose 0.3%, in line with estimates.</li>
<li>Personal spending rose 0.4% month-over-month in February after a 0.3% contraction in January, but missing expectations for a 0.5% increase.</li>
<li>Personal income growth accelerated to 0.8%, above January&#8217;s 0.7% and well beyond the 0.4% estimate.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44534992/how-to-earn-500-a-month-from-pvh-stock-ahead-of-q4-earnings">How To Earn $500 A Month From PVH Stock Ahead Of Q4 Earnings</a></li>
</ul>
Photo: Shutterstock

WOLF

Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected

DBV Technologies shares are trading higher after the company announced up to $307 million in financing to advance the Viaskin Peanut program.

<h3>Gainers</h3>
<ul>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock rose 158.8% to $12.19 during Friday's pre-market session. The market value of their outstanding shares is at $20.0 million. </li>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) stock rose 106.53% to $0.72. The company's market cap stands at $259.5 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares moved upwards by 61.12% to $6.3. The company's market cap stands at $129.2 million. </li>
<li>Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) shares increased by 17.14% to $0.8. The company's market cap stands at $44.0 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock moved upwards by 15.59% to $0.6. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) stock increased by 15.51% to $1.02. The company's market cap stands at $16.9 million. As per the press release, Q4 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Milestone Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) stock fell 61.8% to $0.86 during Friday's pre-market session. The company's market cap stands at $45.8 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares declined by 24.12% to $0.04. The market value of their outstanding shares is at $1.0 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock decreased by 24.0% to $0.19. The company's market cap stands at $1.3 million. </li>
<li>Dermata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) shares decreased by 20.43% to $1.13. The company's market cap stands at $6.1 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) stock fell 20.26% to $3.11. The company's market cap stands at $117.1 million. </li>
<li>Design Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) shares declined by 16.23% to $3.51. The company's market cap stands at $199.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DRMA

DSGN

IRIX

RNAZ

SERA

12 Health Care Stocks Moving In Friday's Pre-Market Session

U.S. stock futures fell on Friday after two consecutive days of decline on Wednesday and Thursday. Futures of major benchmark indices were lower in premarket trading.
Stocks slid as investors digested the new auto tariffs levied on foreign cars and auto parts.
President Donald Trump also warned that he would impose much higher tariffs on the EU and Canada if they retaliate against his planned tariffs.
In a Truth Social post, he threatened large-scale tariffs to counter any economic harm from the two allies. While he has recently hinted at targeting them in his upcoming "Liberation Day" tariffs, no direct actions have been taken yet.
Traders will watch out for the Federal Reserve&#8217;s preferred measure of inflation, the Personal Consumption Expenditures Price Index, specifically the core PCE, which excludes food and energy prices due to their volatility.
With the 10-year Treasury yield at 4.32% and the 2-year at 3.99%, the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a> shows markets pricing in an 88.4% likelihood of the Federal Reserve maintaining current interest rates through its May meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.40%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.22%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.15%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.12%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, dropped in premarket on Friday. The SPY was down 0.19% to $565.98, while the QQQ declined 0.36% to $479.89, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Most sectors on the S&amp;P 500 ended in the red on Thursday, with energy, communication services, and information technology stocks leading the losses. However, health care and consumer staples stocks managed to buck the trend, closing higher.
European automakers were hit hard, with Mercedes-Benz Group AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MBGAF#OTC">MBGAF</a>) sliding 1.7% and Porsche Automobil Holding SE (OTC:<a class="ticker" href="https://www.benzinga.com/stock/POAHF#OTC">POAHF</a>) dropping 2.3%.
In earnings news, shares of TD Synnex Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) tumbled around 14% after the company reported its first-quarter results. Verint Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) also fell sharply, dropping more than 13% following worse-than-expected fourth-quarter earnings and weaker-than-expected FY26 EPS guidance.
On the economic front, U.S. initial jobless claims dipped by 1,000 to 224,000 for the week ending March 22, slightly below market estimates of 225,000. Meanwhile, fourth-quarter GDP growth was revised up to an annualized 2.4% from 2.3%, and U.S. wholesale inventories increased by 0.3% in February, following a 0.8% gain in January.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.53%</td>
<td>17,804.03</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.33%</td>
<td>5,693.31</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.37%</td>
<td>42,299.70</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.39%</td>
<td>2,065.70</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
According to the analysts at BlackRock, the weight of non-U.S. equities in global equity indexes has been on the rise since the end of January. This is caused by the policy uncertainty, which has shaken the investor belief in the U.S. growth and equity strength, pulling the S&amp;P 500 down more than 3%, the note added.
&#8220;The selloff has been exacerbated by investors rapidly pulling out of popular trades – like the tech-heavy momentum equity style factor and cyclical trades that were betting on a boost from growth from potential U.S. deregulation and tax cuts.&#8221;
&#8220;We stay overweight U.S. stocks on a six- to 12-month tactical horizon. Yet prolonged uncertainty could hurt both U.S. and global risk assets,&#8221; the note adds.
Meanwhile, as the uncertainty around tariffs mounts, Michael Townsend, managing director of legislative and regulatory affairs with Schwab, said that &#8220;The White House has been sending mixed signals.&#8221;
&#8220;First, saying that they would be imposed on all countries, then more recently saying they will initially focus on 10 to 15 countries with which the U.S. has big trade deficits. The plan also was to announce tariffs on automobiles, pharmaceuticals, and semiconductors next week, but those reportedly will be delayed. The uncertainty is driving companies and investors crazy.&#8221;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Friday:
<ul>
<li>Personal income, spending, personal consumption expenditure index, and core PCE index are scheduled to be released at 8:30 a.m. ET.</li>
</ul>
<ul>
<li>Consumer sentiment data is scheduled to be released at 10 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Super League Enterprise Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) jumped 7.32% in premarket on Friday ahead of its earnings before the opening bell. Analysts expect a quarterly loss of 26 cents per share on the revenue of $5.50 million.</li>
</ul>
<ul>
<li>Katapult Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPLT#NASDAQ">KPLT</a>) was down 2.16% as Wall Street expects it to report a quarterly loss of $1.77 per share on revenue of $62.20 million before the opening bell.</li>
</ul>
<ul>
<li>Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) slumped 10.84% as it sees full-year 2025 earnings in the range of $14.95 to $15.15 per share, versus estimates of $15.30 per share.</li>
</ul>
<ul>
<li>Braze Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) surged 10.63% after it reported better-than-expected fourth-quarter financial results and issued strong FY26 adjusted EPS guidance.</li>
</ul>
<ul>
<li>AAR Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) was up 2.41% after posting upbeat earnings for the third quarter, while sales missed estimates.</li>
</ul>
<ul>
<li>Direct Digital Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) plunged 38.35% after it reported a substantial earnings miss in the fourth quarter, with earnings per share of -$0.54, sharply below the forecasted $0.11.</li>
</ul>
<ul>
<li>XTI Aerospace Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) dropped 31.30% after announcing a public offering of common stock and warrants; the offering&#8217;s size and valuation remain undisclosed. Proceeds will repay debt and fund operations. This move follows a recent $5 million share buyback.</li>
</ul>
<ul>
<li>Dermata Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) plummeted 21.13% as it announced an agreement for the exercise of 4,834,470 outstanding warrants at a reduced price of $1.284 per share.</li>
</ul>
<ul>
<li>Sensei Biotherapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) climbed 26.60% after reporting encouraging Phase 1/2 trial results for solnerstotug, showing a 14% overall response rate in resistant tumors, significantly exceeding historical rechallenge rates.</li>
</ul>
<ul>
<li>DBV Technologies SA ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) surged 59.85% after securing up to $306.9 million in financing for its Viaskin peanut patch program, including $125.5 million upfront and potentially $181.4 million from warrant exercises.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.06% to hover around $69.88 per barrel.
Gold Spot US Dollar advanced 0.47% to hover around $3,071.22 per ounce. Its fresh record high stood at $3,086.08 per ounce.
Asian markets closed on a lower note on Friday. China&#8217;s CSI 300, India's S&amp;P BSE Sensex, Hong Kong's Hang Seng, South Korea's Kospi, and Japan's Nikkei 225 index declined, whereas Australia's ASX 200 index rose. European markets were also lower in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44528015/trump-reacts-to-selloff-following-auto-tariffs-that-can-take-care-of-itself-in-one-day-two-days-or-o">Trump Reacts To Selloff Following Auto Tariffs: &#8216;That Can Take Care Of Itself In One Day, Two Days, Or One Week&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Government

Market Summary

Futures

Treasuries

Economics

Federal Reserve

ETFs

BRZE

DRCT

KPLT

LULU

MERCEDES BENZ GROUP AG by Mercedes Benz Group AG

MBGAF

Porsche Automobil Holding SE Stuttgart Pref No VTG RTS

POAHF

VRNT

US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets'

Press Releases

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

DBV Technologies Reports First Quarter 2025 Financial Results

DBV Technologies to Participate in the Citizens JMP Life Sciences Conference

Information regarding the total number of voting rights and   total number of shares of the Company as of April 30, 2025

Combined General Meeting of June 11, 2025

DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

Comments

DBV Technologies

DBV Technologies (DBVT) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL